Moderna Shares Slide as Recent Rally Cools Ahead of Earnings

Moderna (MRNA) is down 5.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be profit-taking and a valuation reset rather than a new negative company announcement. This could be because the stock had surged sharply in recent weeks on flu-vaccine optimism, while many recent analyst price targets still sit well below where the shares had been trading, and investors are now repositioning ahead of second-quarter results.

Details:

MRNA had climbed about 31% over the last 30 days and more than 100% over the last year before today’s pullback, showing how extended the stock had become after its recent rally.

Recent analyst updates in early July kept relatively cautious views in place, with several price targets still materially below the stock’s market price even after modest target increases.

The company’s first-quarter update showed a net loss of about $1.3 billion, including a large non-recurring litigation settlement charge, which may have kept some investors cautious despite management reaffirming its 2026 plan.

Moderna’s standalone flu vaccine moved forward with an FDA advisory committee review in June, but with that catalyst already widely recognized, traders may now be waiting for the next concrete update, including the July 31 earnings report.

Sources:

SEC, FDA, Moderna Investor Relations, Benzinga, FinanceCharts

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MRNA Insider Trading Activity

$MRNA insiders have traded $MRNA stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:

STEPHEN HOGE (President) has made 0 purchases and 3 sales selling 266,681 shares for an estimated $13,136,172.
SHANNON THYME KLINGER (Chief Legal Officer) has made 0 purchases and 2 sales selling 17,356 shares for an estimated $899,596.
NOUBAR AFEYAN sold 9,263 shares for an estimated $433,878
ABBAS HUSSAIN sold 5,682 shares for an estimated $264,951

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive MRNA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$MRNA Hedge Fund Activity

We have seen 340 institutional investors add shares of $MRNA stock to their portfolio, and 258 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 17,626,713 shares (+62.9%) to their portfolio in Q1 2026, for an estimated $848,197,429
CAPITAL WORLD INVESTORS added 5,869,654 shares (+45.8%) to their portfolio in Q1 2026, for an estimated $282,447,750
BLACKROCK, INC. removed 2,869,857 shares (-8.8%) from their portfolio in Q1 2026, for an estimated $138,097,518
GOLDMAN SACHS GROUP INC added 2,653,078 shares (+67.2%) to their portfolio in Q1 2026, for an estimated $127,666,113
WELLINGTON MANAGEMENT GROUP LLP added 2,274,302 shares (+2730.4%) to their portfolio in Q1 2026, for an estimated $109,439,412
TWO SIGMA INVESTMENTS, LP added 1,744,308 shares (+23.8%) to their portfolio in Q1 2026, for an estimated $83,936,100
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 1,560,559 shares (-96.6%) from their portfolio in Q1 2026, for an estimated $75,094,099

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MRNA Analyst Ratings

Wall Street analysts have issued reports on $MRNA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Piper Sandler issued a "Overweight" rating on 02/23/2026

To track analyst ratings and price targets for $MRNA, check out Quiver Quantitative's $MRNA forecast page.

$MRNA Price Targets

Multiple analysts have issued price targets for $MRNA recently. We have seen 8 analysts offer price targets for $MRNA in the last 6 months, with a median target of $46.5.

Here are some recent targets:

Matthew Harrison from Morgan Stanley set a target price of $39.0 on 07/08/2026
Luca Issi from RBC Capital set a target price of $45.0 on 07/07/2026
Dimple Gosai from B of A Securities set a target price of $38.0 on 07/07/2026
Edward Tenthoff from Piper Sandler set a target price of $77.0 on 06/26/2026
Salveen Richter from Goldman Sachs set a target price of $49.0 on 05/04/2026
Cory Kasimov from Evercore ISI Group set a target price of $50.0 on 05/04/2026
Eliana Merle from UBS set a target price of $45.0 on 05/04/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.